NeoGenomics/NEO

$14.09

-2.96%
-
1D1W1MYTD1YMAX

About NeoGenomics

NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.

Ticker

NEO

Sector

Healthcare

Trading on

NASDAQ

Industry

Healthcare Facilities

CEO

Christopher Smith

Employees

2,100

Headquarters

Fort myers, United States

NeoGenomics Metrics

BasicAdvanced
$1.85B
Market cap
-
P/E ratio
-$0.70
EPS
1.11
Beta
-
Dividend rate
$1.85B
1.10807
$21.22
$11.03
897.61K
6.197
5.946
57.162
57.162
-5.14%
-9.07%
-5.44%
3.119
1.956
40.428
16.07%
39.65%
10.01%

What the Analysts think about NeoGenomics

Analyst Ratings

Majority rating from 13 analysts.
Buy

Price Targets

Average projection from 11 analysts.
52.95% upside
High $30.00
Low $18.00
$14.09
Current price
$21.55
Average price target

NeoGenomics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-9.19% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$155.5M
2.37%
Net income
$-14.3M
-22.7%
Profit margin
-9.19%
-24.49%

NeoGenomics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 220.37%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.09
-$0.05
-
$0.03
-
Expected
-$0.15
-$0.11
-$0.07
-$0.02
-$0.05
Surprise
-40.52%
-55.96%
-
-220.37%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for NeoGenomics stock?

NeoGenomics (NEO) has a market cap of $1.85B as of April 12, 2024.

What is the P/E ratio for NeoGenomics stock?

The price to earnings (P/E) ratio for NeoGenomics (NEO) stock is 0 as of April 12, 2024.

Does NeoGenomics stock pay dividends?

No, NeoGenomics (NEO) stock does not pay dividends to its shareholders as of April 12, 2024.

When is the next NeoGenomics dividend payment date?

NeoGenomics (NEO) stock does not pay dividends to its shareholders.

What is the beta indicator for NeoGenomics?

NeoGenomics (NEO) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the NeoGenomics stock price target?

The target price for NeoGenomics (NEO) stock is $21.55, which is 52.95% above the current price of $14.09. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell NeoGenomics stock

Buy or sell NeoGenomics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing